Dominari Holdings Dividend

Dividend criteria checks 0/6

Dominari Holdings does not have a record of paying a dividend.

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield	2.9%
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Earnings per share	-US$3.86
Dividend yield forecast in 3Y	n/a

Recent dividend updates

No updates

Recent updates

Here's Why We're Not Too Worried About AIkido Pharma's (NASDAQ:AIKI) Cash Burn Situation

Sep 29

We Think AIkido Pharma (NASDAQ:AIKI) Can Easily Afford To Drive Business Growth

Jun 05

AIkido Pharma's stock surges on psilocybin patent license agreement

Jan 06

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if DOMH's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if DOMH's dividend payments have been increasing.

Dividend Yield vs Market

Dominari Holdings Dividend Yield vs Market

How does DOMH dividend yield compare to the market?
Segment	Dividend Yield
Company (DOMH)	n/a
Market Bottom 25% (US)	1.6%
Market Top 25% (US)	4.8%
Industry Average (Biotechs)	2.9%
Analyst forecast in 3 Years (DOMH)	n/a

Notable Dividend: Unable to evaluate DOMH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate DOMH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate DOMH's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as DOMH has not reported any payouts.

Dominari Holdings Dividend

Dividend criteria checks 0/6

Key information

Recent dividend updates

Recent updates

New minor risk - Share price stability

CEO & Chairman recently bought US$140k worth of stock

Dominari Holdings Inc. Announces Appointment of Mr. Kyle Wool as President

New minor risk - Shareholder dilution

Dominari Holdings Inc. Announces Executive Changes

New major risk - Market cap size

Dominari Holdings Inc. Announces Resignation of Paul Lemire as Member of the Board of Directors and Member of Audit Committee, Compensation Committee, and Nominating Committee

Dominari Holdings Inc. Announces Management Changes

New minor risk - Shareholder dilution

Dominari Holdings Inc., Annual General Meeting, Sep 21, 2023

New major risk - Financial position

Dominari Holdings Inc. Appoints Kyle Wool as CEO of Dominari Securities LLC

Dominari Holdings Inc. Appoints Matthew B. McCullough as the General Counsel

CEO, Principal Financial Officer recently bought US$103k worth of stock

Dominari Holdings Inc. Appoints Christopher Devall as Chief Operating Officer

AIkido Pharma Inc.(NasdaqCM:DOMH) dropped from NASDAQ Composite Index

AIkido Pharma Inc. (NasdaqCM:AIKI) announces an Equity Buyback for $2 million worth of its shares.

Price target decreased to US$16.00

High number of new directors

AIkido continues to buyback more shares

AIkido Pharma's subsidiary agrees to buy broker-dealer firm

Shalom Auerbach made an offer to acquire additional 96.2% stake in AIkido Pharma Inc. (NasdaqCM:AIKI) for $40.4 million.

Alkido Pharma shareholders proposes to acquire company at $8/share in cash

High number of new directors

AIkido Pharma Regains Compliance with NASDAQ Listing Requirements

AIkido Pharma Inc. Appoints Soo Yu as Director

Shalom Auerbach Issues an Open Letter to Board of Directors of AIkido Pharma

AIkido Pharma Inc. (NasdaqCM:AIKI) acquired an unknown stake in Databricks, Inc.

AIkido Pharma (NASDAQ:AIKI) Is In A Good Position To Deliver On Growth Plans

High number of new and inexperienced directors

AIkido Pharma Inc., Annual General Meeting, May 16, 2022

AIkido Pharma Inc. Reports Improved Manufacturing Process and New United States Patent for Pancreatic Drug

AIkido Pharma: Advancing Anticancer And Antiviral Therapies

AIkido Pharma Inc. (NasdaqCM:AIKI) announces an Equity Buyback for $3 million worth of its shares.

AIkido Pharma (NASDAQ:AIKI) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not Too Worried About AIkido Pharma's (NASDAQ:AIKI) Cash Burn Situation

Aikido Pharma Files Patent Application for the Use of Ketamine to Treat Alzheimer's Disease

We Think AIkido Pharma (NASDAQ:AIKI) Can Easily Afford To Drive Business Growth

AIkido Pharma Inc. Announces Phase 1 Data to Be Presented at the American Society of Clinical Oncology Annual Meeting

Aikido Pharma Provides Update on Its Antiviral Platform, Including the Virus That Causes COVID-19

New 90-day high: US$1.91

Aikido Pharma Inc. Appoints Scott T. Tagawa, M.D. to Scientific Advisory Board

AIkido Pharma Inc. Appoints Neil H. Bander as Company's Scientific Advisory Board

New 90-day high: US$1.21

AIkido Pharma Inc. Executes Licensing Agreement for Psilocybin for Cancer Applications

AIkido Pharma's stock surges on psilocybin patent license agreement

New 90-day high: US$0.73

AIkido Pharma Inc. Announces Publication of Artificial Intelligence-Machine Learning Sponsored Research Program for Pancreatic Cancer

New 90-day high: US$0.67

Aikido Pharma Inc. Announces Publication of Positive Results from A Study of Antiviral Activity of FDA Approved Drugs

New 90-day low: US$0.54

New 90-day low: US$0.55

New 90-day high - US$1.23

Earnings released

AIkido Pharma Regains Compliance with NASDAQ Minimum Bid Price Listing Requirements

Stability and Growth of Payments

Dividend Yield vs Market

Earnings Payout to Shareholders

Cash Payout to Shareholders

Discover strong dividend paying companies